Novo Nordisk loses 70% of its market value after setbacks in obesity drugs
Novo Nordisk's market value has dropped by 70% from its peak of $1,000 billion two years ago.
Published 3h1 sourceImportant
Lire en français
≈ 21s
The fact
The Danish lab faced multiple setbacks in developing obesity treatments.
It unveils a strategy to regain competitiveness against rivals like Eli Lilly.
Click the link to read an article on the topic: